Focus on SARS-CoV-22022-05-18T12:20:17+02:00
SARS-CoV-2 NEWS
SARS-CoV-2 PUBLICATIONS

Focus on SARS-CoV-2

SARS-CoV-2 and the clinical features of COVID-19 dramatically highlight the need to better understand why some patients are so strikingly more susceptible to a viral respiratory pathogen. Several researchers involved in RESIST are successfully working to solve this challenge. They are seeking new diagnostic methods, improving vaccines and cloning broadly neutralising monoclonal antibodies.

On this page, we have bundled publications on research related to SARS-CoV-2, as well as news related to the topic of corona infections. It also contains videos and press releases explaining the research, as well as questions and their answers about the topic. We will be happy to keep you up to date.

RESIST-News about SARS-CoV-2

Research on COVID-19

31. March 2022|

What works against SARS-CoV-2? Who falls ill despite vaccination? What role do genes play in the immune response? Numerous questions continue to revolve around the topic of corona. In order to be able to answer them, the "COVID-19 Research Network Lo [...]

The third dose

17. November 2021|

The third vaccination – is it really necessary to be protected against Corona? Who should get vaccinated? In this interview, Prof. Schulz answers questions about the third vaccination as protection against Corona. Prof. Schulz, do we need a third va [...]

The third dose

9. June 2021|

How long does the vaccination protection against SARS-CoV-2 last? Are ongoing vaccinations necessary? Prof. Schulz tells us what is currently known about it: Professor Schulz, how long is one protected against SARS-CoV-2 after the double vaccination [...]

RESIST-News Overview

RESIST Publications on SARS-CoV-2

  1. The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses. Schreiber A, Viemann D, Schöning J, Schloer S, Mecate Zambrano A, Brunotte L, Faist A, Schöfbänker M, Hrincius E, Hoffmann H, Hoffmann M, Pöhlmann S, Rescher U, Planz O, Ludwig S.  Cell Mol Life Sci. 2022 Jan 10;79(1):65.
  2. Optical genome mapping identifies rare structural variations as predisposition factors associated with severe COVID-19. Sahajpal NS, Jill Lai CY, Hastie A, Mondal AK, Dehkordi SR, van der Made CI, Fedrigo O, Al-Ajli F, Jalnapurkar S, Byrska-Bishop M, Kanagal-Shamanna R, Levy B, Schieck M, Illig T, Bacanu SA, Chou JS, Randolph AG, Rojiani AM, Zody MC, Brownstein CA, Beggs AH, Bafna V, Jarvis ED, Hoischen A, Chaubey A, Kolhe R; COVID19hostgenomesv consortium.  iScience. 2022 Jan 10:103760.
  3. Wahrnehmung der Corona-Pandemie durch Neurodermitispatienten – Ergebnisse aus dem Neurodermitisregister TREATgermany. Helmert C, Siegels D, Haufe E, Abraham S, Heratizadeh A, Kleinheinz A, Harder I, Schäkel K, Effendy I, Wollenberg A, Sticherling M, Stahl M, Worm M, Schwichtenberg U, Schwarz B, Rossbacher J, Buck PM, Schenck F, Werfel T, Weidinger S, Schmitt J; das TREATgermany Studienteam. J Dtsch Dermatol Ges. 2022 Jan;20(1):45-58.
  4. Robust induction of neutralizing antibodies against the SARS-CoV-2 Delta variant after homologous Spikevax or heterologous Vaxzevria-Spikevax vaccination. Hammerschmidt SI, Thurm C, Bošnjak B, Bernhardt G, Reinhold A, Willenzon S, Ritter C, Reinhold D, Schraven B, Förster R.  Eur J Immunol. 2022 Feb;52(2):356-359.
  5. Dysregulated PI3K Signaling in B Cells of CVID Patients. Harder I, Münchhalfen M, Andrieux G, Boerries M, Grimbacher B, Eibel H, Maccari ME, Ehl S, Wienands J, Jellusova J, Warnatz K, Keller B. Cells. 2022 Jan 28;11(3):464. doi: 10.3390/cells11030464.
  6. NK cell dysfunction in severe COVID-19: TGF-β-induced downregulation of integrin beta-2 restricts NK cell cytotoxicity. Barros-Martins J, Förster R, Bošnjak B.  Signal Transduct Target Ther. 2022 Jan 31;7(1):32.
  7. Clinical development and approval of COVID-19 vaccines. Kalinke U, Barouch DH, Rizzi R, Lagkadinou E, Türeci Ö, Pather S, Neels P.  Expert Rev Vaccines. 2022 Feb 14.
  8. Evolution of biofilm-adapted gene expression profiles in lasR-deficient clinical Pseudomonas aeruginosa isolates. Jeske A, Arce-Rodriguez A, Thöming JG, Tomasch J, Häussler S. NPJ Biofilms Microbiomes. 2022 Feb 14;8(1):6.
  9. Toll-like receptors matter: plasmacytoid dendritic cells in COVID-19. Becker J, Kalinke U. EMBO J. 2022 Apr 26:e111208. doi: 10.15252/embj.2022111208. Epub ahead of print.
  10. Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern. Odak I, Schultze-Florey CR, Hammerschmidt SI, Ritter C, Willenzon S, Friedrichsen M, Ravens I, Sikora R, Bayir LM, Gutierrez Jauregui R, Bernhardt G, Stankov MV, Cossmann A, Hansen G, Krey T, Cornberg M, Koenecke C, Behrens GMN, Bošnjak B, Förster R.  Front Immunol. 2022 Mar 14;13:863039. doi: 10.3389/fimmu.2022.863039. PMID: 35359969; PMCID: PMC8964088.
  11. Clinical development and approval of COVID-19 vaccines. Expert Rev Vaccines.  Kalinke U, Barouch DH, Rizzi R, Lagkadinou E, Türeci Ö, Pather S, Neels P.  2022 May;21(5):609-619.
  12. Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern. Odak I, Schultze-Florey CR, Hammerschmidt SI, Ritter C, Willenzon S, Friedrichsen M, Ravens I, Sikora R, Bayir LM, Gutierrez Jauregui R, Bernhardt G, Stankov MV, Cossmann A, Hansen G, Krey T, Cornberg M, Koenecke C, Behrens GMN, Bošnjak B, Förster R. Front Immunol. 2022 Mar 14;13:863039.
  1. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos G, Dopfer-Jablonka A, Heidemann A, Ritter C, Friedrichsen M, Schultze-Florey C, Ravens I, Willenzon S, Bubke A, Ristenpart J, Janssen A, Ssebyatika G, Bernhardt G, Münch J, Hoffmann M, Pöhlmann S, Krey T, Bošnjak B, Förster R, Behrens GMN. Nat Med. 2021 Jul 14. doi: 10.1038/s41591-021-01449-9. Online ahead of print. PMID: 34262158
  2. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination. Tscherne A, Schwarz JH, Rohde C, Kupke A, Kalodimou G, Limpinsel L, Okba NMA, Bošnjak B, Sandrock I, Odak I, Halwe S, Sauerhering L, Brosinski K, Liangliang N, Duell E, Jany S, Freudenstein A, Schmidt J, Werner A, Gellhorn Serra M, Klüver M, Guggemos W, Seilmaier M, Wendtner CM, Förster R, Haagmans BL, Becker S, Sutter G, Volz A. Proc Natl Acad Sci U S A. 2021 Jul 13;118(28):e2026207118. doi: 10.1073/pnas.2026207118. PMID: 34162739 Free PMC article.
  3. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination. Tscherne A, Schwarz JH, Rohde C, Kupke A, Kalodimou G, Limpinsel L, Okba NMA, Bošnjak B, Sandrock I, Odak I, Halwe S, Sauerhering L, Brosinski K, Liangliang N, Duell E, Jany S, Freudenstein A, Schmidt J, Werner A, Gellhorn Serra M, Klüver M, Guggemos W, Seilmaier M, Wendtner CM, Förster R, Haagmans BL, Becker S, Sutter G, Volz A.  Proc Natl Acad Sci U S A. 2021 Jul 13;118(28):e2026207118. doi: 10.1073/pnas.2026207118. PMID: 34162739.
  4. Development of the reproduction number from coronavirus SARS-CoV-2 case data in Germany and implications for political measures. Khailaie S, Mitra T, Bandyopadhyay A, Schips M, Mascheroni P, Vanella P, Lange B, Binder SC, Meyer-Hermann M. BMC Med. 2021 Jan 28;19(1):32. doi: 10.1186/s12916-020-01884-4. PMID: 33504336 Free PMC article.
  5. Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy. Bošnjak B, Odak I, Ritter C, Stahl K, Graalmann T, Steinbrück L, Blasczyk R, Falk CS, Schulz TF, Wedemeyer HH, Cornberg M, Ganser A, Förster R, Koenecke C. Front Immunol. 2021 Aug 12;12:721738
  6. Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents. Bošnjak B, Odak I, Barros-Martins J, Sandrock I, Hammerschmidt SI, Permanyer M, Patzer GE, Greorgiev H, Gutierrez Jauregui R, Tscherne A, Schwarz JH, Kalodimou G, Ssebyatika G, Ciurkiewicz M, Willenzon S, Bubke A, Ristenpart J, Ritter C, Tuchel T, Meyer Zu Natrup C, Shin DL, Clever S, Limpinsel L, Baumgärtner W, Krey T, Volz A, Sutter G, Förster R. Front Immunol. 2021 Nov 11;12:772240.
  7. Robust induction of neutralizing antibodies against the SARS-CoV-2 Delta variant after homologous Spikevax or heterologous Vaxzevria-Spikevax vaccination. Hammerschmidt SI, Thurm C, Bošnjak B, Bernhardt G, Reinhold A, Willenzon S, Ritter C, Reinhold D, Schraven B, Förster R. Eur J Immunol. 2021 Dec 6.
  8. Long-Lasting Immunity Against SARS-CoV-2: Dream or Reality? Gussarow D, Bonifacius A, Cossmann A, Stankov MV, Mausberg P, Tischer-Zimmermann S, Gödecke N, Kalinke U, Behrens GMN, Blasczyk R, Eiz-Vesper B. Front Med (Lausanne). 2021 Nov 25;8:770381.
  1. Safety and efficacy of abatacept in patients with treatment-resistant SARCoidosis (ABASARC) – protocol for a multi-center, single-arm phase IIa trial. Frye BC, Rump IC, Uhlmann A, Schubach F, Ihorst G, Grimbacher B, Zissel G, Quernheim JM.Contemp Clin Trials Commun. 2020 May 29;19:100575. doi: 10.1016/j.conctc.2020.100575. PMID: 32551397; PMCID: PMC7292904.
  2. Reappearance of effector T cells is associated with recovery from COVID-19. EBioMedicine. 2020 Jul;57:102885. doi: 10.1016/j.ebiom.2020.102885. Epub 2020 Jul 7. PMID: 32650275; PMCID: PMC7338277. Odak I, Barros-Martins J, Bošnjak B, Stahl K, David S, Wiesner O, Busch M, Hoeper MM, Pink I, Welte T, Cornberg M, Stoll M, Goudeva L, Blasczyk R, Ganser A, Prinz I, Förster R, Koenecke C, Schultze-Florey CR.
  3. Combating COVID-19: MVA Vector Vaccines Applied to the Respiratory Tract as Promising Approach Toward Protective Immunity in the Lung. Förster R, Fleige H, Sutter G. Front Immunol. 2020 Aug 7;11:1959. doi: 10.3389/fimmu.2020.01959. PMID: 32849655; PMCID: PMC7426738.
  4. Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals. Behrens GMN, Cossmann A, Stankov MV, Schulte B, Streeck H, Förster R, Bosnjak B, Willenzon S, Boeck AL, Thu Tran A, Thiele T, Graalmann T, Kayser MZ, Zychlinsky Scharff A, Dopfer C, Horke A, Pink I, Witte T, Wetzke M, Ernst D, Jablonka A, Happle C. Infect Dis Ther. 2020 Dec;9(4):837-849. doi: 10.1007/s40121-020-00334-1. Epub 2020 Sep 4. PMID: 32886335; PMCID: PMC7472691.
  5. COVID-19 related reduction in pediatric emergency healthcare utilization – a concerning trend. Dopfer C, Wetzke M, Zychlinsky Scharff A, Mueller F, Dressler F, Baumann U, Sasse M, Hansen G, Jablonka A, Happle C. BMC Pediatr. 2020 Sep 7;20(1):427. doi: 10.1186/s12887-020-02303-6. PMID: 32894080; PMCID: PMC7475725.
  6. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. Bošnjak B, Stein SC, Willenzon S, Cordes AK, Puppe W, Bernhardt G, Ravens I, Ritter C, Schultze-Florey CR, Gödecke N, Martens J, Kleine-Weber H, Hoffmann M, Cossmann A, Yilmaz M, Pink I, Hoeper MM, Behrens GMN, Pöhlmann S, Blasczyk R, Schulz TF, Förster R.  Cell Mol Immunol. 2020 Nov 2:1–9. doi: 10.1038/s41423-020-00573-9. Epub ahead of print. PMID: 33139905; PMCID: PMC7604543.
  7. Double-edge anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods Bosnjak B, Stein SC, Willenzon S, Cordes AK, Puppe W, Bernhardt G, Ravens I, Ritter C, Schultze-Florey CR, Gödecke N, Martens J, Kleine-Weber H, Hoffmann M, Cossmann A, Yilmaz M, Pink I, Hoeper MM, Behrens GMN, Pöhlmann S, Blasczyk R, Schulz TF, Forster R.  Cell Mol Immunol 2020
Go to Top